Finance

Beta
Lists
ALMKT:EPA
Mauna Kea Technologies SA
€0.17
-1.49%
(-0.0026) 1D
Jun 3, 5:35:09 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALMKT...
Open
€0.18
High
€0.18
Low
€0.17
Mkt. cap
31.46M
Avg. vol.
632.53K
Volume
450.82K
52-wk high
€0.23
52-wk low
€0.07
EPS
-€0.14
Shares outstanding
192.10M
No. of employees
61
Open
€0.18
High
€0.18
Low
€0.17
Mkt. cap
31.46M
Avg. vol.
632.53K
Volume
450.82K
52-wk high
€0.23
52-wk low
€0.07
EPS
-€0.14
Shares outstanding
192.10M
No. of employees
61
News stories
From sources across the web
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts. The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time. Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOSacha Loiseau
Employees61
Founded2000
Headquarters-
SectorMedical device
Websitemaunakeatech.com
Last report
Jan 15, 2026
Fiscal period
Q4 2025
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
2.44M / -
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.02M
2.02M
2.44M
2.44M
Cost of goods sold
396.00K
396.00K
528.00K
528.00K
Cost of revenue
396.00K
396.00K
528.00K
528.00K
Research and development expenses
818.50K
818.50K
861.00K
861.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.90M
1.90M
1.89M
1.89M
Operating expense
3.02M
3.02M
3.11M
3.11M
Total operating expenses
3.41M
3.41M
3.64M
3.64M
Operating income
-1.40M
-1.40M
-1.20M
-1.20M
Other non operating income
-695.00K
-695.00K
10.84M
10.84M
EBT including unusual items
-2.31M
-2.31M
7.69M
7.69M
EBT excluding unusual items
-2.20M
-2.20M
8.06M
8.06M
Income tax expense
28.00K
28.00K
-35.50K
-35.50K
Effective tax rate
-1.21%
-1.21%
-0.46%
-0.46%
Other operating expenses
83.00K
83.00K
92.00K
92.00K
Net income
-2.33M
-2.33M
7.72M
7.72M
Net profit margin
-115.83%
-115.83%
316.50%
316.50%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-6.50K
-6.50K
-490.50K
-490.50K
Net interest expenses
-6.50K
-6.50K
-490.50K
-490.50K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.35M
-1.35M
-1.11M
-1.11M
Gain or loss from assets sale
-
-
281.00K
281.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer